Clearside Biomedical

Data support adding suprachoroidal injection to anti-VEGF for RVOResults from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Suprachoroidal injection of triamcinolone acetonide for uveitis proves promisingResults of a 6-month phase I/II clinical trial of suprachoroidal injection of triamcinolone for noninfectious uveitis showed the treatment was safe and well tolerated.
Sustained drug delivery moving toward clinical use“New Horizons in Glaucoma Drug Delivery” session reviewed nine development programs. Some companies are focusing on micro- and nano-scale particles, others on gels and solid drug depots. All aim for controlled, steady state delivery over specific time periods to enhance drug delivery to the target tissue and improve therapeutic outcomes.